Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Chimerix Inc
CMRX | US
0.88
USD-0.00
-0.11%
CMRX | US
About Chimerix Inc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
21/10/2024
Close
0.88
Open
0.88
High
0.89
Low
0.87
Chimerix Inc. a biopharmaceutical company develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 2 clinical trial for treating tumors which harbor the H3 K27M mutation in glioma patients; ONC206 an imipridone Dopamine Receptor D2 (DRD2) antagonist and caseinolytic protease P (ClpP) agonist that demonstrated enhanced non-competitive DRD2 antagonism relative to ONC201 which is in Phase I clinical trials to treat solid tumors; ONC212 an imipridone agonist of the orphan G protein-coupled receptors (GPCR) tumor suppressor GPR132 as well as ClpP for solid tumors and hematological malignancies including pancreatic cancer and leukemias; and CMX521 a nucleoside analog antiviral drug candidate for the treatment of SARS-CoV-2 (COVID-19) infection. The company has license agreement with SymBio Pharmaceuticals to develop and commercialize TEMBEXA for human diseases other than orthopoxviruses including smallpox. Chimerix Inc. was incorporated in 2000 and is headquartered in Durham North Carolina.
View LessCMRX | US
Risk
53.9
Sharpe
-0.38
Luna's Score
55/100
Recommendation
Hold
Luna says (CMRX | US)
What's Working
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Strong Revenue Growth (> 10%)
What's not Working
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Operating Margin (< 10%)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
43.3%1 month
53.9%3 months
65.7%6 months
54.9%Returns
Fundamental Ratios
PE
-
Fwd. PE
1.21
Price to book
0.50
Debt to equity
0.01
Debt to assets
0.01
Ent. to EBITDA
1.03
Ent. to rev.
3.57
PEG
-
Other Fundamentals
EBITDA
-94.63M
MarketCap
78.88M
MarketCap(USD)
78.88M
Div. yield
-
Op. margin
-17.70K
Erngs. growth
-
Rev. growth
396.20
Ret. on equity
-44.62
Short ratio
9.90
Short perc.
2.12
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Range10D
0.15
Range1M
0.15
Range3M
0.44
Volumes: Market Activity
Rel. volume
0.83
Price X volume
96.35K
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 1.03 | - | Expensive |
| Ent. to Revenue | 3.57 | - | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 0.50 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 65.74 | - | Par |
| Debt to Equity | 0.01 | -1.23 | Expensive |
| Debt to Assets | 0.01 | 0.25 | Cheaper |
| Market Cap | 78.88M | - | Emerging |
